Jump to navigation ☰ Menu Regenerations Ahead Biostage is a biotechnology company developing bioengineered organ implants to treat congenital defects, cancers and other life-threatening conditions of the esophagus, bronchus and trachea. The company’s novel Cellframe™ technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Our Cellframe technology is based on over 20 years of scientific progress in the fields of tissue engineering, cell biology and material science. Cellframe technology combines the best attributes of a synthetic scaffold with tissue engineering and cell biology to create what may be a revolutionary method of addressing organ damage. Biostage has been developing its new generation of organ implants as a platform capable of being used in the esophagus and main airways (trachea and bronchi). The current platform, based on our Cellframe technology, represents a complete re-engineering of our earlier organ scaffold and cell technology to better stimulate the regenerative properties of each of these organs. Biostage’s Cellframe technology platform is used to create organ specific Cellspan implants. Recent large animal data showed promising results as our Cellframe technology applied to the esophagus achieved the regeneration of esophageal tissue. Privacy Policy Terms of Use Search Contact ©2021 Biostage. All rights reserved.

Jump to navigation ☰ Menu Cellspan Esophageal Implants Cellspan Esophageal Implants may offer improved outcomes for patients by potentially simplifying surgical techniques to reduce post-operative complications, improve quality of life and enable regeneration of the patient’s own esophagus. Cellspan implants are intended to offer numerous advantages over standard surgical resection: Eliminate use of the stomach or intestine to create a mock esophagus Reduce complications and improve post-surgical morbidity Use in patients who are not fit for surgery Reduce costs through reduced hospitalization and morbidity rates Cellspan Esophageal Implants for Pediatric Esophageal Atresia Biostage is developing its Cellspan esophageal implant for the treatment of esophageal atresia. Esophageal atresia is a birth disorder of the digestive system in which the esophagus does not develop properly. In most cases, the upper esophagus does not connect with the lower esophagus and stomach. Esophageal atresia occurs in about 1 in every 4,000 live births worldwide. Cellspan Esophageal Implants for Esophageal Cancer With about 16,910 new esophageal cancer cases estimated in 2016 in the U.S., Cellspan implants have the potential to improve outcomes and change treatment paradigms. Privacy Policy Terms of Use Search Contact ©2021 Biostage. All rights reserved.